Lataa...
Acute dasatinib exposure commits Bcr-Abl–dependent cells to apoptosis
Pioneering work with the Bcr-Abl inhibitor, imatinib, demonstrated a requirement for constant Bcr-Abl inhibition to achieve maximal therapeutic benefit in treating chronic myeloid leukemia (CML), establishing a paradigm that has guided further drug development for this disease. Surprisingly, the sec...
Tallennettuna:
| Päätekijät: | , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society of Hematology
2009
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2765681/ https://ncbi.nlm.nih.gov/pubmed/19706883 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-10-113969 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|